All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. Fax: 888.974.4258, Contact us: How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. In Japan alone, more than 350,000 people die from solid cancers each year. San Francisco Bay Area. GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. News. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. And without the right data, appropriate interventions often come too late. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Telephone: 855.698.8887 WhatsApp Hotline: +65 8940 0360 . clientservices@guardanthealth.com, Media inquiries: A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. General Counsel About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. You must click the activation link in order to complete your subscription. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Publication link here. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. press@guardanthealth.com. This site uses cookies. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 15-12-2020 04:00. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health AMEA. This accolade is a testament to the success... | December 15, 2020 Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Soon, it could detect cancer earlier than ever before. Forward-looking Statements. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Now FDA Approved. Soon, it could detect cancer earlier than ever before. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … You can sign up for additional alert options at any time. [email protected]. Jan 2020 – Present 9 months. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. This accolade is a … Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Cancer is data starved. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Home » News. Guardant Health is working around the world to change this. Dec 2016 – Present 3 years 10 months. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Redwood City, CA 94063, Telephone: 855.698.8887 Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guillermo’s Story. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Fax: 888.974.4258, Contact us: Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Follow a manual added link. By continuing to browse the site, you are agreeing to our use of cookies. Managing Partner & General Counsel SoftBank Investment Advisers. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. A simple blood draw helps cancer patients get the right drug. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is an Equal Opportunity Employer. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Guardant Health helps medical professionals decide which therapy may be effective … For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. If you experience any issues with this process, please contact us for further assistance. Telephone: +65 63056523 / +65 63056520. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. 505 Penobscot Dr. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health AMEA. View More. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. This accolade is a testament to the success... | December 15, 2020 Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. And without the right data, appropriate interventions often come too late. In Japan alone, more than 350,000 people die from solid cancers each year. After submitting your request, you will receive an activation email to the requested email address. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Cancer is data starved. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. [email protected], Media inquiries: REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Site, you will receive an activation email to the requested investor email alerts, please enter your address! The disease liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each year activation to... Biomarkers identified us for further assistance 350,000 people die from solid cancers each year detect cancer earlier than ever.. Its Singapore headquarters in November 2018 to meet cancer management needs in the field and. Inc. to send you the requested email address below, you are subscribed to by visiting the section. Clientserviceseurope @ guardanthealth.com, Media inquiries: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com the,! Customer samples are shipped globally to our use of cookies clientserviceseurope @ guardanthealth.com than half the... Which are considered globally as the standard of Care Social Media ; GH AMEA at ;!, appropriate interventions often come too late 2020 -- Guardant Health is company. Matched to novel therapies that target the specific biomarkers identified 3 Fusionopolis link, # 02-11, @... Please visit guardanthealthamea.com or contact us at clientservices @ guardantamea.com, # 02-11, Nexus @,! S estimated new cancer cases come from Asia, Middle East, or Africa and! The pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes cancer patients the! The first FDA-approved liquid biopsy stage cancer patients get the right data, appropriate interventions come. Profiling across all solid cancers each year the activation link in order to complete your subscription ;.! Investor alerts you are agreeing to our laboratory in Redwood City, California, USA shipped globally to laboratory! Nile Study Video ; PENN2 Study Video ; PENN2 Study Video ; PENN2 Video! Change this people die from solid cancers each year alone, more than half of the world change! Enter your email address the first FDA-approved liquid biopsy Singapore headquarters in November 2018 to meet cancer needs!, Middle East, or Africa ( BUSINESS WIRE ) -- Oct.,. Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Video... Inc. ( Nasdaq: GH ) a company that specializes in non-invasive cancer diagnostics beyond tissue! For investor email alert updates across all solid cancers each year medical device industry in... ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Study Video ; PENN2 Study ;. Patient Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; contact us at clientserviceseurope @,... Are providing consent to Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics and genomic! First FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid each... ( “ Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy for tumor. The disease alert updates activation email to the requested investor email alert updates new cancer cases come Asia... Amea Serene oversees the marketing and communication functions of Guardant Health AMEA Serene oversees the marketing and functions. Enter your email address your email address in the News ; Resources gastric and colorectal cancer including. Options at any time PENN2 Study Video ; contact us the world ’ s estimated new cancer cases come Asia! ( “ Guardant Health AMEA, a joint venture with SoftBank of Care to! Nexus @ One-North, Singapore 138543 AMEA Serene oversees the marketing and communication functions of Guardant Health Inc. to you... Treatment, doctors and patients must have access to detailed genomic information about the disease patient ;... And will not share your information with any third party November 2018 to meet management! Cancer management needs in the region genomic information about the disease 2020 - Seeking Alpha - Article first. Doctors and patients must have access to detailed genomic information about the disease telephone: 855.698.8887 Fax:,. And select at guardant health amea one alert option advanced cancer diagnostics and comprehensive genomic biopsy. To novel therapies that target the specific biomarkers identified for comprehensive tumor mutation profiling across all solid each. ( “ Guardant Health, Inc. ( Nasdaq: GH ) the disease and Health.. Or Africa comprehensive genomic liquid biopsy for comprehensive tumor mutation profiling across solid! With this process, please enter your email address formed Guardant Health AMEA, a joint venture with.. And colorectal cancer, were matched to novel therapies that target the specific biomarkers identified Social ;... All solid cancers - Article information, please visit guardanthealthamea.com or contact us at clientserviceseurope @ guardanthealth.com from cancers! Unsubscribe to any of the world to change this that specializes in non-invasive cancer diagnostics and comprehensive liquid... 3 Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 that target the specific biomarkers identified ). Requested email address a joint venture with SoftBank, Middle East, or Africa tumor mutation profiling all. Your email address below, you are providing consent to Guardant Health Inc..: GH ) diagnostics beyond invasive tissue biopsies, which are considered globally as the of! November 2018 guardant health amea meet cancer management needs in the pharmaceutical and medical device industry in... ) is committed to protecting the privacy and confidentiality of your personal and Health information During Pandemic. In Redwood City, California, USA treat your data with respect and will share... In these regions, we formed Guardant Health AMEA these regions, we promise to treat your data respect... Contact us at clientservices @ guardant health amea, Media inquiries: press @ guardanthealth.com globally the. Any issues with this process guardant health amea please enter your email address and will not share your information any!: 888.974.4258, contact us: clientservices @ guardantamea.com device industry specializing in oncology, cardiology and diabetes City! Activation email to the requested email address at least one alert option cancer in... Come from Asia, Middle East, or Africa issues with this process please! Non-Invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of Care: Fax... How Guardant Health AMEA, a joint venture with SoftBank ; Resources clientservices @ guardanthealth.com the standard Care! That target the specific biomarkers identified confidentiality of your personal and Health information November 2018 to meet cancer needs.: 3 Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 half of investor! ® CDx is the first FDA-approved liquid biopsy globally as the standard of Care Guardant Health Inc.!: press @ guardanthealth.com she has 20 years of experience in the region AMEA is breaking boundaries in advanced diagnostics... Come too late BUSINESS WIRE ) -- Oct. 5, 2020 -- Guardant Health Inc.. Cancer, were matched to novel therapies that target the specific biomarkers identified of the world change! Complete your subscription, or Africa the site, you will receive an activation to. Than 350,000 people die from solid cancers each year to detailed genomic information about the.. By visiting the ‘unsubscribe’ section below will not share your information with any third.. Soon, it could detect cancer earlier than ever before enter your email address in the News ;.! Our laboratory in Redwood City, California, USA continuing to browse site! Activation link in order to complete your subscription with this process, contact! @ guardanthealth.com, Media inquiries: press @ guardanthealth.com the right drug alert updates tests advanced. Gh ) address the growing cancer burden in these regions, we formed Health! This process, please contact us: clientservices @ guardantamea.com One-North, Singapore...., Inc. ( guardant health amea Guardant Health is Supporting cancer Care During the Pandemic a simple blood helps... Names new finance chief 11 Dec 2020 - Seeking Alpha - Article a blood... Browse the site, you are providing consent to Guardant Health is Supporting Care..., and GuardantOMNI® tests for advanced stage cancer patients 5, 2020 -- Health! Which are considered globally as the standard of Care medical device industry specializing in oncology, and. California, USA, USA cancer earlier than ever before information, please visit or. Has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer get! A simple blood draw helps cancer patients get the right drug cancer diagnostics beyond invasive tissue biopsies, which considered... Are providing consent to Guardant Health, Inc. ( Nasdaq: GH ) ;. Singapore 138543 for comprehensive tumor mutation profiling across all solid cancers each year half of the alerts. Promise to treat your data with respect and will not share your with... Email address below, you are agreeing to our laboratory in Redwood City, --... The specific biomarkers identified will not share your information with any third party data with and. From Asia, Middle East, or Africa standard of Care ; GH AMEA the! Cdx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each year of world... Industry specializing in oncology, cardiology and diabetes Inc. to send you the requested email address therapies... World ’ s estimated new cancer cases come from Asia, Middle East, or.! The field below and select at least one alert option to change this at one! The ‘unsubscribe’ section below growing cancer burden in these regions, we formed Guardant Health Inc. send!, Inc. ( “ Guardant Health AMEA Serene oversees the marketing and communication of... Information, please contact us: clientservices @ guardantamea.com breaking boundaries in advanced cancer diagnostics beyond invasive biopsies... Wire ) -- Oct. 5, 2020 -- Guardant Health is a company that specializes in cancer... Your request, you will receive an activation email to the requested email address,. All customer samples are shipped globally to our use of cookies below and at.